NYSE:BIO - Bio-Rad Laboratories Stock Price, Price Target & More

$259.48 +0.63 (+0.24 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$258.85
Today's Range$258.15 - $260.75
52-Week Range$208.95 - $279.59
Volume48,418 shs
Average Volume158,126 shs
Market Capitalization$7.72 billion
P/E Ratio63.29
Dividend YieldN/A
Beta0.94

About Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories logoBio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products include reagents, instruments, and software which address specific niches within the in vitro diagnostics (IVD) test market. This segment sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. It operates in Europe, Pacific Rim, the United States, and internationally. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:BIO
CUSIP09057220
Phone510-724-7000

Debt

Debt-to-Equity Ratio0.15%
Current Ratio3.93%
Quick Ratio2.75%

Price-To-Earnings

Trailing P/E Ratio63.29
Forward P/E Ratio45.28
P/E Growth3.01

Sales & Book Value

Annual Sales$2.16 billion
Price / Sales3.58
Cash Flow$4.1464 per share
Price / Cash62.58
Book Value$98.38 per share
Price / Book2.64

Profitability

EPS (Most Recent Fiscal Year)$4.10
Net Income$122.24 million
Net Margins5.31%
Return on Equity3.63%
Return on Assets2.48%

Miscellaneous

Employees3,270
Outstanding Shares29,800,000

Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How will Bio-Rad Laboratories' stock buyback program work?

Bio-Rad Laboratories declared that its Board of Directors has approved a share repurchase program on Wednesday, November 29th 2017, which allows the company to repurchase $250,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories (NYSE:BIO) released its quarterly earnings data on Tuesday, February, 27th. The medical research company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.22. The medical research company had revenue of $620.43 million for the quarter, compared to the consensus estimate of $618.89 million. Bio-Rad Laboratories had a net margin of 5.31% and a return on equity of 3.63%. View Bio-Rad Laboratories' Earnings History.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Bio-Rad Laboratories.

What price target have analysts set for BIO?

5 brokers have issued 1-year price objectives for Bio-Rad Laboratories' stock. Their forecasts range from $255.00 to $325.00. On average, they expect Bio-Rad Laboratories' stock price to reach $298.75 in the next year. View Analyst Ratings for Bio-Rad Laboratories.

Who are some of Bio-Rad Laboratories' key competitors?

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 68)
  • Ms. Christine A. Tsingos, Chief Financial Officer and Exec. VP (Age 59)
  • Mr. John Goetz, Former Exec. VP & COO (Age 68)
  • Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 62)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 56)

Has Bio-Rad Laboratories been receiving favorable news coverage?

Press coverage about BIO stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bio-Rad Laboratories earned a daily sentiment score of 0.10 on Accern's scale. They also assigned news headlines about the medical research company an impact score of 44.33 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $259.48.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $7.72 billion and generates $2.16 billion in revenue each year. The medical research company earns $122.24 million in net income (profit) each year or $4.10 on an earnings per share basis. Bio-Rad Laboratories employs 3,270 workers across the globe.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


MarketBeat Community Rating for Bio-Rad Laboratories (BIO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  421
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe BIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bio-Rad Laboratories (NYSE:BIO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Bio-Rad Laboratories in the last 12 months. Their average twelve-month price target is $298.75, suggesting that the stock has a possible upside of 15.13%. The high price target for BIO is $325.00 and the low price target for BIO is $255.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.803.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $298.75$298.75$273.3333$260.00
Price Target Upside: 15.13% upside13.91% upside3.81% upside13.25% upside

Bio-Rad Laboratories (NYSE:BIO) Consensus Price Target History

Price Target History for Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories (NYSE:BIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/20/2018Wells FargoBoost Price TargetOutperform$280.00 -> $290.00LowView Rating Details
2/28/2018Jefferies GroupBoost Price TargetTop Pick -> Buy$325.00HighView Rating Details
2/28/2018CitigroupBoost Price TargetBuy$325.00HighView Rating Details
2/16/2018CL KingDowngradeBuy -> NeutralMediumView Rating Details
9/18/2017Deutsche BankReiterated RatingBuy$255.00LowView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Bio-Rad Laboratories (NYSE:BIO) Earnings History and Estimates Chart

Earnings by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories (NYSE:BIO) Earnings Estimates

2018 EPS Consensus Estimate: $5.50
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.68$0.68$0.68
Q2 20181$1.17$1.17$1.17
Q3 20181$1.33$1.33$1.33
Q4 20181$2.32$2.32$2.32

Bio-Rad Laboratories (NYSE BIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$1.13N/AView Earnings Details
2/27/2018Q4 2017$1.28$1.50$618.89 million$620.43 millionViewN/AView Earnings Details
11/2/2017Q3 2017$0.54$0.91$507.99 million$535.00 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.63$0.58$515.04 million$504.67 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.27$0.41$477.76 million$500.05 millionViewListenView Earnings Details
2/23/2017Q416$1.03($0.70)$574.40 million$571.45 millionViewN/AView Earnings Details
11/1/2016Q316$0.51$0.62$480.60 million$508.75 millionViewN/AView Earnings Details
8/3/2016Q2$1.13$0.61$497.80 million$516.80 millionViewN/AView Earnings Details
5/5/2016Q1$0.60$0.42$463.90 million$471.20 millionViewN/AView Earnings Details
2/25/2016Q415$1.27$1.68$570.80 million$570.56 millionViewListenView Earnings Details
11/3/2015Q315$0.54$0.59$495.55 million$469.96 millionViewN/AView Earnings Details
8/6/2015Q215$0.78$0.97$494.85 million$506.10 millionViewN/AView Earnings Details
5/5/2015Q115$0.33$0.61$474.60 million$472.80 millionViewN/AView Earnings Details
2/26/2015Q414$1.18$1.34$593.41 million$598.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.86$0.39$525.40 million$530.64 millionViewN/AView Earnings Details
8/5/2014Q214$0.95$1.09$537.58 million$536.80 millionViewN/AView Earnings Details
5/6/2014Q114$0.80$0.23$515.00 million$509.30 millionViewN/AView Earnings Details
2/27/2014Q413$1.42$1.04$586.67 million$602.60 millionViewListenView Earnings Details
11/7/2013Q313$0.91($0.25)$529.02 million$505.10 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.25$1.20$532.60 million$525.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.03$0.68$506.34 million$499.70 millionViewN/AView Earnings Details
2/26/2013Q4 2012$1.33$1.65$558.68 million$573.80 millionViewN/AView Earnings Details
11/6/2012Q312$1.14$1.48$507.79 million$498.70 millionViewN/AView Earnings Details
8/7/2012$1.19$1.69ViewN/AView Earnings Details
5/1/2012$1.02$1.09ViewN/AView Earnings Details
2/23/2012$1.67$2.08ViewN/AView Earnings Details
11/1/2011$1.53$1.61ViewN/AView Earnings Details
8/2/2011$1.47$1.41ViewN/AView Earnings Details
5/3/2011$1.32$1.16ViewN/AView Earnings Details
2/24/2011$1.35$2.41ViewN/AView Earnings Details
11/2/2010Q3 2010$1.17$1.59ViewN/AView Earnings Details
8/3/2010Q2 2010$1.27$1.35ViewN/AView Earnings Details
5/4/2010Q1 2010$1.17$1.24ViewN/AView Earnings Details
2/24/2010Q4 2009$1.08$1.49ViewN/AView Earnings Details
11/3/2009Q3 2009$1.00$1.38ViewN/AView Earnings Details
8/4/2009Q2 2009$1.03$1.37ViewN/AView Earnings Details
5/5/2009Q1 2009$0.98$1.10ViewN/AView Earnings Details
2/26/2009Q4 2008$0.90$1.18ViewN/AView Earnings Details
11/6/2008Q3 2008$1.06$1.01ViewN/AView Earnings Details
8/5/2008Q2 2008$1.08$1.58ViewN/AView Earnings Details
5/6/2008Q1 2008$0.99$0.97ViewN/AView Earnings Details
2/28/2008Q4 2007$0.80$0.92ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Bio-Rad Laboratories (NYSE:BIO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Bio-Rad Laboratories (NYSE BIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.29%
Institutional Ownership Percentage: 64.39%
Insider Trading History for Bio-Rad Laboratories (NYSE:BIO)
Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories (NYSE BIO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2017Christine A TsingosCFOSell4,980$249.40$1,242,012.007,283View SEC Filing  
12/4/2017Michael CrowleyEVPSell1,000$258.39$258,390.002,492View SEC Filing  
11/30/2017James R. StarkVPSell746$270.51$201,800.46View SEC Filing  
11/14/2017Giovanni MagniEVPSell2,400$253.01$607,224.009,251View SEC Filing  
8/11/2017Michael CrowleyEVPSell700$215.91$151,137.002,060View SEC Filing  
3/7/2017Michael CrowleyEVPSell300$196.13$58,839.002,760View SEC Filing  
11/9/2016James R. StarkVPSell1,299$171.42$222,674.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bio-Rad Laboratories (NYSE BIO) News Headlines

Source:
DateHeadline
Head-To-Head Review: Bio-Rad Laboratories (BIO) & PerkinElmer (PKI)Head-To-Head Review: Bio-Rad Laboratories (BIO) & PerkinElmer (PKI)
www.americanbankingnews.com - April 25 at 7:18 PM
Bio-Rad Laboratories (BIO) Expected to Post Earnings of $0.90 Per ShareBio-Rad Laboratories (BIO) Expected to Post Earnings of $0.90 Per Share
www.americanbankingnews.com - April 25 at 7:16 PM
Bio-Rad Laboratories (BIO) Scheduled to Post Quarterly Earnings on WednesdayBio-Rad Laboratories (BIO) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 5:47 AM
Why BIOTON SA.’s (WSE:BIO) Investor Composition Impacts Your ReturnsWhy BIOTON SA.’s (WSE:BIO) Investor Composition Impacts Your Returns
finance.yahoo.com - April 24 at 4:52 PM
Bio-Rad to Report First-Quarter 2018 Financial ResultsBio-Rad to Report First-Quarter 2018 Financial Results
finance.yahoo.com - April 18 at 4:54 PM
Wells Fargo Initiates Coverage on Bio-Rad Laboratories (BIO)Wells Fargo Initiates Coverage on Bio-Rad Laboratories (BIO)
www.americanbankingnews.com - April 18 at 1:58 PM
Bio-Rad Laboratories to Post Q2 2018 Earnings of $1.17 Per Share, Jefferies Group Forecasts (BIO)Bio-Rad Laboratories to Post Q2 2018 Earnings of $1.17 Per Share, Jefferies Group Forecasts (BIO)
www.americanbankingnews.com - April 18 at 8:05 AM
Jefferies Group Comments on Bio-Rad Laboratories Q1 2018 Earnings (BIO)Jefferies Group Comments on Bio-Rad Laboratories' Q1 2018 Earnings (BIO)
www.americanbankingnews.com - April 17 at 6:12 AM
Bio-Rad Laboratories (BIO) Receives Consensus Recommendation of "Buy" from BrokeragesBio-Rad Laboratories (BIO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 14 at 1:25 AM
Express Scripts (ESRX) to Launch Pilot Program, Shares UpExpress Scripts (ESRX) to Launch Pilot Program, Shares Up
finance.yahoo.com - April 13 at 4:40 PM
Where BIOTON SA. (WSE:BIO) Stands In Earnings Growth Against Its IndustryWhere BIOTON SA. (WSE:BIO) Stands In Earnings Growth Against Its Industry
finance.yahoo.com - April 12 at 4:39 PM
Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?
finance.yahoo.com - April 12 at 10:04 AM
Texas Hospital Administers Cerner's (CERN) Millenium SystemTexas Hospital Administers Cerner's (CERN) Millenium System
finance.yahoo.com - April 10 at 4:40 PM
Here's Why You Should Invest in Fresenius Medical Right NowHere's Why You Should Invest in Fresenius Medical Right Now
finance.yahoo.com - April 10 at 9:39 AM
Bio-Rad Laboratories (BIO) Expected to Post Quarterly Sales of $530.35 MillionBio-Rad Laboratories (BIO) Expected to Post Quarterly Sales of $530.35 Million
www.americanbankingnews.com - April 10 at 2:18 AM
Stryker Loses 7.6% in a Month: What's Weighing It Down?Stryker Loses 7.6% in a Month: What's Weighing It Down?
finance.yahoo.com - April 9 at 4:36 PM
GNC Holdings Partners Rapid Nutrition, Forays in AustraliaGNC Holdings Partners Rapid Nutrition, Forays in Australia
finance.yahoo.com - April 9 at 4:36 PM
 Analysts Expect Bio-Rad Laboratories (BIO) Will Post Earnings of $0.98 Per Share Analysts Expect Bio-Rad Laboratories (BIO) Will Post Earnings of $0.98 Per Share
www.americanbankingnews.com - April 8 at 9:14 PM
Bio-Rad Laboratories (BIO) Upgraded to Buy by ValuEngineBio-Rad Laboratories (BIO) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - April 3 at 6:59 PM
Accuray's CyberKnife Treats First Patient at Erasmus MCAccuray's CyberKnife Treats First Patient at Erasmus MC
finance.yahoo.com - March 28 at 4:36 PM
Should You Buy Walgreens Boots (WBA) Ahead of Earnings?Should You Buy Walgreens Boots (WBA) Ahead of Earnings?
finance.yahoo.com - March 27 at 4:32 PM
Baxter (BAX) Banks on Portfolio Strength, Strategic BuyoutsBaxter (BAX) Banks on Portfolio Strength, Strategic Buyouts
finance.yahoo.com - March 27 at 4:32 PM
Veeva Systems' Vault QMS to Manage Shionogi Product QualityVeeva Systems' Vault QMS to Manage Shionogi Product Quality
finance.yahoo.com - March 27 at 4:32 PM
Here's Why You Should Invest in athenaheath Stock Right NowHere's Why You Should Invest in athenaheath Stock Right Now
finance.yahoo.com - March 27 at 4:32 PM
Here's Why You Should Steer Clear of DENTSPLY (XRAY) for NowHere's Why You Should Steer Clear of DENTSPLY (XRAY) for Now
finance.yahoo.com - March 26 at 4:31 PM
Wright Medical Expands Product Index for Advanced DiagnosisWright Medical Expands Product Index for Advanced Diagnosis
finance.yahoo.com - March 26 at 4:31 PM
Financial Analysis: Bio-Rad Laboratories (BIO) and Restoration Robotics (HAIR)Financial Analysis: Bio-Rad Laboratories (BIO) and Restoration Robotics (HAIR)
www.americanbankingnews.com - March 25 at 3:12 AM
Bio-Rad Laboratories (BIO) Expected to Announce Quarterly Sales of $533.57 MillionBio-Rad Laboratories (BIO) Expected to Announce Quarterly Sales of $533.57 Million
www.americanbankingnews.com - March 24 at 2:02 AM
FDA Nod for Orthofix's G-Beam to Boost Extremity Fixation SBUFDA Nod for Orthofix's G-Beam to Boost Extremity Fixation SBU
finance.yahoo.com - March 23 at 4:40 PM
Detailed Research: Economic Perspectives on CTS, Lindblad Expeditions, AmeriGas Partners, BBX Capital, Bio-Rad Laboratories, and Inter Parfums — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on CTS, Lindblad Expeditions, AmeriGas Partners, BBX Capital, Bio-Rad Laboratories, and Inter Parfums — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - March 23 at 9:14 AM
Bio-Rad Laboratories (BIO) Expected to Announce Earnings of $1.05 Per ShareBio-Rad Laboratories (BIO) Expected to Announce Earnings of $1.05 Per Share
www.americanbankingnews.com - March 22 at 9:14 PM
Bio-Rad receives non-compliance notice from NYSE over 10-K delayBio-Rad receives non-compliance notice from NYSE over 10-K delay
seekingalpha.com - March 22 at 9:29 AM
Abbott's MitraClip Therapy Wins Reimbursement Nod From MHLWAbbott's MitraClip Therapy Wins Reimbursement Nod From MHLW
finance.yahoo.com - March 20 at 4:32 PM
FDA Nod for Edwards' Acumen HPI Software Widens PortfolioFDA Nod for Edwards' Acumen HPI Software Widens Portfolio
finance.yahoo.com - March 20 at 4:32 PM
Bio-Rad Laboratories (BIO) Outperform Rating Reiterated at Wells FargoBio-Rad Laboratories' (BIO) Outperform Rating Reiterated at Wells Fargo
www.americanbankingnews.com - March 20 at 11:31 AM
Bio-Rad Laboratories (BIO) Given Consensus Rating of "Buy" by AnalystsBio-Rad Laboratories (BIO) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 20 at 1:46 AM
What's Driving Orthofix International to a New 52-Week HighWhat's Driving Orthofix International to a New 52-Week High
finance.yahoo.com - March 19 at 4:33 PM
Thermo Fisher Scientific Buys IntegenX, Widens HID SuiteThermo Fisher Scientific Buys IntegenX, Widens HID Suite
finance.yahoo.com - March 19 at 4:33 PM
BioScrip's Dull 2017 Earnings a Woe, Core Business RobustBioScrip's Dull 2017 Earnings a Woe, Core Business Robust
finance.yahoo.com - March 16 at 5:38 PM
Orthofix to Buy Spinal Kinetics, Widens Spine Fixation SuiteOrthofix to Buy Spinal Kinetics, Widens Spine Fixation Suite
finance.yahoo.com - March 16 at 5:38 PM
What Do Analysts Think About Bio-Rad Laboratories Inc’s (NYSE:BIO) Future?What Do Analysts Think About Bio-Rad Laboratories Inc’s (NYSE:BIO) Future?
finance.yahoo.com - March 16 at 9:31 AM
Global nucleic acid amplification testing market expected to be driven by increasing prevalence of infectious diseasesGlobal nucleic acid amplification testing market expected to be driven by increasing prevalence of infectious diseases
www.marketwatch.com - March 15 at 5:09 PM
Global molecular weight marker market expected to be driven by huge investments on R&D in the field of molecular biologyGlobal molecular weight marker market expected to be driven by huge investments on R&D in the field of molecular biology
www.marketwatch.com - March 15 at 9:06 AM
Laborie Medical Technologies to Acquire Cogentix MedicalLaborie Medical Technologies to Acquire Cogentix Medical
finance.yahoo.com - March 14 at 10:10 AM
IDEXX Laboratories Gains on Solid Prospects & CAG BusinessIDEXX Laboratories Gains on Solid Prospects & CAG Business
www.zacks.com - March 12 at 11:24 AM
Heres Why You Should Invest in Bio-Rad (BIO) Right NowHere's Why You Should Invest in Bio-Rad (BIO) Right Now
www.msn.com - March 10 at 5:33 PM
Veeva Systems Vault Clinical Platform to Aid Ora's OperationsVeeva Systems Vault Clinical Platform to Aid Ora's Operations
finance.yahoo.com - March 8 at 5:35 PM
$533.57 Million in Sales Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter$533.57 Million in Sales Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter
www.americanbankingnews.com - March 7 at 6:54 AM
Schroder Investment Management Group Has $1.09 Million Holdings in Bio-Rad Laboratories, Inc. (BIO)Schroder Investment Management Group Has $1.09 Million Holdings in Bio-Rad Laboratories, Inc. (BIO)
www.americanbankingnews.com - March 6 at 10:52 AM
Bio-Rad Laboratories, Inc. (BIO) Expected to Post Earnings of $1.05 Per ShareBio-Rad Laboratories, Inc. (BIO) Expected to Post Earnings of $1.05 Per Share
www.americanbankingnews.com - March 5 at 5:24 PM

SEC Filings

Bio-Rad Laboratories (NYSE:BIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bio-Rad Laboratories (NYSE:BIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bio-Rad Laboratories (NYSE BIO) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.